| Ytd | 164.34% | |
| 1y | 164.34% |
| Open | 100.00 | Prev Close | 97.93 | Low | 97.14 | High | 101.38 | Mkt Cap | 4.17B |
| Vol | 358.45K | Avg Vol | 719.45K | EPS | -2.50 | P/E | N/A | Forward P/E | -36.41 |
| Beta | N/A | Short Ratio | 4.76 | Inst. Own | 97.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 111.22 | 200-d Avg | 86.89 | 1yr Est | 163.50 |
MANE News
Bamco Inc. NY increased its position in shares of Veradermics, Incorporated (NYSE: MANE) by 284.8% d
Veradermics, Incorporated (NYSE: MANE - Get Free Report) Director John Childs sold 100,000 shares of
Veradermics (NYSE:MANE) reported quarterly losses of $(0.58) per share which beat the analyst consen
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical compan
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for h
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late-stage biopharmaceutical company
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
Veradermics, Incorporated (NYSE: MANE - Get Free Report)'s stock price gapped up before the market o
Citigroup analyst Geoff Meacham maintains Veradermics (NYSE:MANE) with a Buy and raises the price
Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase
Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in
Needham analyst Serge Belanger maintains Veradermics (NYSE:MANE) with a Buy and raises the price
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 fo
Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday
Veradermics NYSE: MANE said results from the female arms of Study 207, a phase II open-label trial o
US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition propo
VDPHL01, a novel orally-administered extended-release minoxidil formulation, achieved fast onset of
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
B. Riley Securities analyst Mayank Mamtani initiates coverage on Veradermics (NYSE:MANE) with a B
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
Jefferies analyst Roger Song maintains Veradermics (NYSE:MANE) with a Buy and raises the price ta
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs
The mean of analysts' price targets for Veradermics (MANE) points to a 27.7% upside in the stock. Wh
LifeSci Capital analyst Rami Katkhuda initiates coverage on Veradermics (NYSE:MANE) with a Outper
Veradermics, Incorporated (MANE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
Wall Street analysts changed outlook on top names: ODTX, MOBI, MANE. See analyst ratings page for al
Needham analyst Serge Belanger initiates coverage on Veradermics (NYSE:MANE) with a Buy rating an
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutic
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutica
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutica
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded,
U.S. stocks trade lower on Monday, with Dow falling 0.1%. Verizon beats Q1 earnings, raises FY26 gui
Veradermics reports Phase 2/3 data for VDPHL01, showing significant hair growth and a safety profile
U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq
VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all
Leerink Partners analyst Marc Goodman maintains Veradermics (NYSE:MANE) with a Outperform and rai
Veradermics (NYSE:MANE) reported quarterly losses of $(0.62) per share which beat the analyst consen
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Veradermics (NYSE:MANE) with a Ov
Citigroup analyst Geoff Meacham initiates coverage on Veradermics (NYSE:MANE) with a Buy rating a
Leerink Partners analyst Marc Goodman initiates coverage on Veradermics (NYSE:MANE) with a Outper
Jefferies analyst Roger Song initiates coverage on Veradermics (NYSE:MANE) with a Buy rating and
This marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss,
